These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22161896)

  • 1. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy.
    Sinnott M; Falzarano SM; Hernandez AV; Jones JS; Klein EA; Zhou M; Magi-Galluzzi C
    Prostate; 2012 Aug; 72(11):1179-86. PubMed ID: 22161896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.
    Falzarano SM; Zhou M; Hernandez AV; Moussa AS; Jones JS; Magi-Galluzzi C
    Urology; 2010 Sep; 76(3):682-7. PubMed ID: 20206973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.
    Abdollah F; Scattoni V; Raber M; Roscigno M; Briganti A; Suardi N; Gallina A; Capitanio U; Freschi M; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Aug; 108(3):366-71. PubMed ID: 21087451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unilateral prostate cancer cannot be accurately predicted in low-risk patients.
    Isbarn H; Karakiewicz PI; Vogel S; Jeldres C; Lughezzani G; Briganti A; Montorsi F; Perrotte P; Ahyai SA; Budäus L; Eichelberg C; Heuer R; Köllermann J; Sauter G; Schlomm T; Steuber T; Haese A; Zacharias M; Fisch M; Heinzer H; Huland H; Chun FK; Graefen M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):784-7. PubMed ID: 19864083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
    Graefen M; Haese A; Pichlmeier U; Hammerer PG; Noldus J; Butz K; Erbersdobler A; Henke RP; Michl U; Fernandez S; Huland H
    J Urol; 2001 Mar; 165(3):857-63. PubMed ID: 11176486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
    Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
    Mouraviev V; Mayes JM; Sun L; Madden JF; Moul JW; Polascik TJ
    Cancer; 2007 Aug; 110(4):906-10. PubMed ID: 17587207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
    Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
    Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
    Obek C; Louis P; Civantos F; Soloway MS
    J Urol; 1999 Feb; 161(2):494-8; discussion 498-9. PubMed ID: 9915434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.